Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 17 Triple Negative Breast Neoplasms 9 Urinary Bladder Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplastic Cells, Circulating 1 Multiple Myeloma 1 Lymphoma, T-Cell, Peripheral 1 Hormone Receptor Positive HER-2 Negative Breast Cancer 1 HR-positive,HER2-negative Breast Cancer 1 HR+/HER2- Breast Cancer 1 HER2-negative Early Breast Cancer 1 HER2-negative Breast Cancer 1 HER2 Positive Early Breast Cancer 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 1 lenvatinib 1 enfortumab vedotin 1 abemaciclib 1 Tablets 1 Standard of Care 1 Radiosurgery 1 Protons 1 Nivolumab 1 Epirubicin 1 Combined Modality Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoma, Adenoid Cystic × Epirubicin × Clear all

NCT07320508 2026-05-12

EIC-SNACC

Eye & ENT Hospital of Fudan University

Phase 2 Recruiting

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡